ORAGENICS INC — Board/Management Information 2021

Sep 3, 2021

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 8-K

Field: Rule-Page

Field: /Rule-Page

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

Date of Report: August 31, 2021

(Date of earliest event reported)

Field: Rule-Page

Field: /Rule-Page

Oragenics, Inc.

(Exact name of registrant as specified in its charter)

FL	001-32188	59-3410522
(State
or other jurisdiction of
incorporation)	(Commission File
Number)	(IRS
Employer Identification
Number)

| 4902
Eisenhower Boulevard , Suite 125 Tampa , FL | 33634 |
| --- | --- |
| (Address
of principal executive offices) | (Zip
Code) |

813 - 286-7900

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock | OGEN | NYSE
American |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 5.08 Shareholder Director Nominations

As a result of the Company’s inability to achieve a quorum in connection with either of its originally scheduled June 30, 2021 Annual Meeting or at its reconvened meeting, on August 31, 2021, the Board of Directors of the Company established that a new rescheduled 2021 Annual Meeting of Shareholders (the “2021 Annual Meeting”) will be held on November 22, 2021. Because the date of the new rescheduled 2021 Annual Meeting has changed by more than 30 days from the anniversary date of the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”), in accordance with Rule 14a−5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is informing shareholders of such change. The record date, time and location of the 2021 Annual Meeting will be as set forth in the Company’s proxy statement for the new rescheduled 2021 Annual Meeting.

Because the date of the new rescheduled 2021 Annual Meeting has been changed by more than 30 days from the anniversary of the 2020 Annual Meeting of Shareholders, a new deadline has been set for submission of proposals by Shareholders intended to be included in the Company’s 2021 proxy statement and form of proxy. Proposals to be included in the Company’s proxy statement for the new rescheduled 2021 Annual Meeting in accordance with Rule 14a-8 under the Exchange Act, must be received by the Company on or before October 1, 2021, which the Company believes is a reasonable time before it expects to begin to print and send its proxy materials for the new rescheduled 2021 Annual Meeting. Shareholders must deliver the proposals or nominations to the Company’s principal executive offices at the following address: Oragenics, Inc., Attn: Corporate Secretary, 4902 Eisenhower Boulevard, Suite 125, Tampa, Florida 33634.

| Exhibit
No. | Description |
| --- | --- |
| 104 | Cover
Page Interactive Data File (embedded within the Inline XBRL document) |

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 3 rd day of September, 2021.

| ORAGENICS,
INC. | |
| --- | --- |
| (Registrant) | |
| BY: | /s/
Michael Sullivan |
| | Michael
Sullivan |
| | Interim
Principal Executive Officer |
| | and
Chief Financial Officer |

Field: Page; Sequence: 3; Options: Last

Field: /Page